Chapter 1505

Yang Rui has never made a complete new drug, which is too time-consuming and unnecessary.

Few pharmaceutical companies in the world will make a new drug and sell it from beginning to end. The same reason is that the normal pharmaceutical companies can't stand the 20-year payment cycle. If a century old shop or a 200 year old enterprise spends all their time on drug development, they will be able to make several drugs in their whole life, and they will have to guard against about 6% of the failure rate

Even the super pharmaceutical companies have their own focuses. For example, Pfizer, the most famous company, has the strongest ability to sell. Of course, this is not to say that their manufacturing and R & D capabilities are weak. For example, sildenafil, the main component of Viagra, was developed by Pfizer's subsidiary.

In history, it took almost six or seven years for them to find suitable active compounds. Then it took five or six years for them to verify that sildenafil had no effect on lowering blood pressure

As for the development of Viagra, it's not so much luck as a fight!

For Pfizer, the failure of developing a new drug is inevitable. In which year, several new drugs should not be declared failure.

But how many decades does a researcher have in his life?

For the researcher in charge of the project, the cost of investment is even higher. It takes him at least 10 years to accumulate experience, maybe 15 to 20 years, to have the opportunity to preside over such a project. This is not the previous academic investment, but a failed new drug, especially the one he presided over in his own life. However, the Japanese are around 80 years old, The clinical trial was stopped, and the dog that did the animal experiment had a disturbing increase in the proportion of malignant tumors.

In 78, Merck Pharma Co., which screened out similar compounds, originally wanted to find a cheap one. Unexpectedly, this situation occurred when it just spent a lot of money on the compounds it wanted to make. In order not to let the previous investment go astray, it had to continue the clinical trial nervously. Finally, fortunately, it succeeded and opened the sales road of lovastatin, a 10 billion class blockbuster.

Therefore, although there is a great chance of pitching people, they can still be sold for money.

Buying and selling compounds is also a very common thing in the pharmaceutical industry.

Yang Rui's compound of deferonone, a milestone in sales, has now won hundreds of millions of dollars. Although the new drug for Gaucher's disease was given to northern pharmaceutical, it was also a good start for Yang Rui, so that foreign enterprises such as Jielikang were willing to take money to participate.

Sildenafil compounds, before 1992, were neither expensive nor cheap.

Pfizer is still looking forward to it: a blood pressure lowering drug, if the effect is good, it is a proper blockbuster. If the annual sales amount is 1 billion US dollars, the profit should be at least several hundred million US dollars.

It's also for this expectation that Pfizer can tolerate spending tens of millions of dollars a year.

However, when sildenafil was proved clinically ineffective around 1992, its value plummeted.

However, Yang Rui is not qualified to go card time.

Even useless compounds will become expensive in Pfizer's hands, which is well known in the market.

If they find something strange, Yang Rui will not be able to cut off his beard.

Therefore, Yang Rui made a decision and sent two employees from Huarui company to contact Pfizer.

At the same time, Yang Rui also let out the wind, saying that Huarui is ready to further develop its pharmaceutical R & D capabilities

Comrade Li Zhangzhen of Huarui company is very happy about this.

As the person in charge of the company, the larger the scale of the company and the more projects, the stronger the sense of achievement.

Compared with the simple work of pharmaceutical sales, the integration of industry, University and research sounds much more handsome.

Comrade Li Zhangzhen's happiness lasted about a week.

In the twinkling of an eye, his excitement disappeared from his eyes. When he met Yang Rui, he was even more depressed: "Pfizer refused."

"Oh, what reason?" Yang Rui was not surprised.

"There's no good reason. They don't want to sell sildenafil yet." With regret in his words, Li Zhang asked again, "do you have any other goals?"

"Pfizer refused so directly?" Yang Rui is more concerned about Li Zhangzhen's attitude. He obviously gives up completely.

Li Zhangzhen nodded helplessly and said, "Pfizer said that since it is a compound favored by Nobel laureate Mr. Yang Rui, they will at least increase their investment to have a try."

"Er..." Yang Rui thought of this possibility, but it was a bit embarrassed to be told directly."The main reason is that sildenafil's safety test is very good, Pfizer still has some illusions about it." Li Zhangzhen sighed.

Yang Rui said, "antihypertensive drugs are commonly used, and patients need to take them every day. There is a lot of competition in the market, and the security is not good, so there is no development value at all. "

"But it's not easy to find safe compounds." Li Zhangzhen said with regret: "Pfizer didn't raise the price, it should be completely uninterested."

"En..." Yang Rui pondered slightly.

"In fact, I have learned that there are many good antihypertensive compounds on the market. If you buy them from a small company, it may be easier..."

"Since it's not about the price, let's look for a breakthrough from another angle." Yang Rui didn't take Li Zhangzhen's advice at all. He said to himself, "if you ask them to consult Pfizer, just say... Market for technology."

"The market? What market? " Li Zhangzhen is still a little disillusioned.

"The Chinese market, of course." Yang Rui, with the attitude of GMP Committee boss, said: "you just tell them that if they don't want to talk with us, Pfizer's new drugs want to enter the Chinese market in the future, they won't have to talk about it."

There should be BGM here!

……